Innovative biotech company launches with a mission to advance personalized therapies for autism.

Baltimore, MD — Autica Bio, a new biotechnology company focused on developing targeted, precision-based therapies for autism spectrum conditions, officially launched today with the goal of transforming autism research and treatment. Led by an accomplished team of scientists and biopharmaceutical leaders, Autica Bio aims to bridge the gap in autism-specific drug discovery through cutting-edge stem cell and high-throughput screening technologies.

Autica Bio leverages a groundbreaking platform that utilizes human-induced pluripotent stem cell (hiPSC) technology to create patient-specific brain organoids, mimicking the unique neurobiological characteristics of autism. This innovative approach allows Autica Bio to develop and test therapeutic candidates with unprecedented precision, targeting the cellular and molecular pathways associated with autism. The company’s proprietary neurophysiological screening platform identifies early biomarkers and novel therapeutic targets, accelerating the path to personalized treatments.

“We are excited to launch Autica Bio and bring advanced science and technology to autism therapeutics,” said Michael W. Nestor, Chief Scientific Officer and Founder of Autica Bio. “Our team’s extensive experience in precision medicine, combined with our commitment to patient-centered research, positions us to make a significant impact on the future of autism therapeutics.”

With autism prevalence rising and limited autism-specific treatments available, Autica Bio is committed developing new approaches to treating autism spectrum conditions. The company plans to achieve key milestones in the coming years, including advancing preclinical development, refining patient-specific screening techniques, and exploring strategic partnerships to bring novel therapies to market.

For more information, please visit www.auticabio.com or contact:
Michael W. Nestor, Ph.D.
Chief Scientific Officer and Founder
Autica Bio
Email: mnauticabio@gmail.com

Support Our Research

Autica Bio is an early-stage drug discovery company dedicated to rigorous science that will drive new therapeutic options. Join us in supporting Autica Bio’s promising research to bring hope to patients and their families.